Gilead Sciences Operating Margin 2006-2021 | GILD

Current and historical operating margin for Gilead Sciences (GILD) over the last 10 years. The current operating profit margin for Gilead Sciences as of September 30, 2021 is 40.34%.
Gilead Sciences Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $27.48B $11.63B 42.31%
2021-06-30 $26.64B $9.79B 36.74%
2021-03-31 $25.56B $4.56B 17.83%
2020-12-31 $24.69B $4.07B 16.49%
2020-09-30 $23.15B $2.51B 10.86%
2020-06-30 $22.17B $-0.96B -4.33%
2020-03-31 $22.72B $4.45B 19.60%
2019-12-31 $22.45B $4.29B 19.10%
2019-09-30 $22.37B $4.34B 19.40%
2019-06-30 $22.36B $8.43B 37.72%
2019-03-31 $22.32B $8.28B 37.11%
2018-12-31 $22.13B $8.20B 37.06%
2018-09-30 $22.28B $9.35B 41.95%
2018-06-30 $23.20B $10.54B 45.42%
2018-03-31 $24.69B $12.51B 50.67%
2017-12-31 $26.11B $14.12B 54.10%
2017-09-30 $27.48B $15.88B 57.78%
2017-06-30 $28.47B $16.47B 57.84%
2017-03-31 $29.10B $16.75B 57.55%
2016-12-31 $30.39B $17.63B 58.02%
2016-09-30 $31.58B $19.21B 60.83%
2016-06-30 $32.37B $20.40B 63.00%
2016-03-31 $32.84B $21.47B 65.39%
2015-12-31 $32.64B $22.19B 68.00%
2015-09-30 $31.45B $20.90B 66.47%
2015-06-30 $29.19B $18.80B 64.39%
2015-03-31 $27.49B $17.59B 64.01%
2014-12-31 $24.89B $15.27B 61.33%
2014-09-30 $20.70B $12.13B 58.62%
2014-06-30 $17.44B $9.80B 56.20%
2014-03-31 $13.67B $6.54B 47.86%
2013-12-31 $11.20B $4.52B 40.39%
2013-09-30 $10.67B $4.43B 41.56%
2013-06-30 $10.31B $4.33B 41.98%
2013-03-31 $9.95B $4.24B 42.55%
2012-12-31 $9.70B $4.01B 41.33%
2012-09-30 $9.31B $3.77B 40.48%
2012-06-30 $9.01B $3.73B 41.40%
2012-03-31 $8.74B $3.69B 42.19%
2011-12-31 $8.39B $3.79B 45.20%
2011-09-30 $8.18B $3.75B 45.85%
2011-06-30 $8.00B $3.73B 46.59%
2011-03-31 $7.79B $3.70B 47.54%
2010-12-31 $7.95B $3.96B 49.84%
2010-09-30 $7.98B $4.20B 52.59%
2010-06-30 $7.85B $4.11B 52.42%
2010-03-31 $7.57B $3.88B 51.30%
2009-12-31 $7.01B $3.53B 50.33%
2009-09-30 $6.41B $3.17B 49.55%
2009-06-30 $5.98B $2.97B 49.77%
2009-03-31 $5.61B $2.82B 50.28%
2008-12-31 $5.34B $2.68B 50.22%
2008-09-30 $5.00B $2.48B 49.62%
2008-06-30 $4.69B $2.34B 49.79%
2008-03-31 $4.46B $2.27B 50.94%
2007-12-31 $4.23B $2.16B 51.16%
2007-09-30 $4.03B $0.10B 2.40%
2007-06-30 $3.72B $-0.39B -10.53%
2007-03-31 $3.36B $-0.57B -16.96%
2006-12-31 $3.03B $-0.76B -25.05%
2006-09-30 $2.74B $1.16B 42.21%
2006-06-30 $2.48B $1.35B 54.23%
2006-03-31 $2.29B $1.26B 54.89%
2005-12-31 $2.03B $1.11B 54.66%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $88.146B $24.689B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09